Contamination by bacterial endotoxins causes a multitude of disorders depending on the affected area, and can lead to sepsis, a systemic inflammatory response syndrome with a mortality rate of about 30%. Thus, the detection of these endotoxins is one of the challenges in the prevention of sepsis but also of other infectious diseases in humans and animals.
EndoQuant is an innovative assay for the direct quantification of endotoxins or lipopolysaccharides (LPS) based on liquid chromatography coupled with tandem mass spectrometry (LCMS2). It allows access to a dosage of the total LPS of many complex media (biological fluids, tissues, food…), independently of the substrate's nature. Unlike other existing methods, EndoQuant allows the detection and quantification of endotoxins in both active and inactive forms.
This very reliable, fast and safe assay provides a new tool for the sepsis diagnosis and the evaluation of the LPS neutralization capacities by different biological media.
MARKETS AND APPLICATIONS
Reliable technology routinely used for public and industrial partners
Laboratory Lipids, Nutrition, Cancer
University of Burgundy - INSERM
European patent registered on November 13th, 2013
Patent licensing / R&D services
+33 (0)6 31 10 21 21